Neumora Therapeutics is trading 13.3% down at $1.43 in thin pre-market action, extending recent volatility after several double-digit daily moves this week.
- The drop appears tied to light liquidity rather than a clear catalyst, with no new company-specific headlines, earnings, or FDA updates reported overnight.
- The downward move contrasts with broader index futures, which are trading modestly higher in early sessions.